Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

Jacob J. Orme,Fadi Taza,Navonil De Sarkar,Alok K. Tewari,Syed Arsalan Naqvi,Irbaz B. Riaz,Daniel S. Childs,Noha Omar,Nabil Adra,Ryan Ashkar,Heather H. Cheng,Michael T. Schweizer,Alexandra O. Sokolova,Neeraj Agarwal,Pedro Barata,Oliver Sartor,Diogo Bastos,Oren Smaletz,Jacob E. Berchuck,Heather McClure

European Urology Oncology（2023）

引用 0|浏览2

暂无评分

摘要

Presence of BRCA2 mutations helps identify a subset of patients with prostate cancer who are likely to benefit from poly (ADP-ribose) polymerase (PARP) inhibitors, but additional biomarkers are needed to better refine patient selection. This study found that concurrent SPOP mutations predict enhanced PARP inhibitor sensitivity and durable progression-free survival in BRCA2-altered castration-resistant prostate cancer.

查看译文

关键词

SPOP mutation,BRCA2 mutation,Poly(ADP-ribose) polymerase inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要